About: Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.43 (+0.35%)
EQ NASDAQ Equillium Inc
Equillium Inc share price
Atividade de preço de EQ
Último preço
$ 1,430
Variação (24h)
0,01 USD (0,35%)
Volume
255.24K
Volume (média 4 sem.)
-
Abertura
$ 1,39
Variação do dia
$ 1,39 - $ 1,48
Fechamento anterior
$ 1,42
Último negócio
29 Oct, 7:51 pm GMT+0
Atrasado
29 Oct, 7:51 pm GMT+0
EQ price performance
Atrasado
29 Oct, 7:51 pm GMT+0
quote.marketSignals